Summary
Development of neuroprotective therapies for multiple sclerosis is dependent on defining the precise mechanisms whereby immune effector cells and molecules are able to induce relatively selective injury of oligodendrocytes (OLs) and their myelin membranes. The selectivity of this injury could be conferred either by the properties of the effectors or the targets. The former would involve antigen specific recognition by either antibody or T cell receptor of the adaptive immune system. OLs are also susceptible to non antigen restricted injury mediated by components of the innate immune system including macrophages/microglia and NK cells. Target related selectivity could reflect the expression of death inducing surface receptors (such as Fas or TNFR-1) required for interaction with effector mediators and subsequent intracellular signaling pathways, including the caspase cascade. Development of therapeutic delivery systems, which would reach the site of disease activity within the CNS, will permit the administration of inhibitors either of the cell death pathway or of effector target inter action and opens new avenues to neuroprotection approach.
Chapter PDF
Similar content being viewed by others
Keywords
- Multiple Sclerosis
- Neuroprotective Therapy
- Myelin Membrane
- Human Oligodendrocyte
- Central Nervous System Virus Infection
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Antel J.P., Williams K, Blain M, McRea E, McLaurin J (1994) Oligodendrocyte lysis by CD4+ T cells independent of tumor necrosis factor. Ann Neurol 35: 341–348
Antel J.P., McCrea E, Ladiwala U, Qin Y.F., Becher B (1998) Non-MHC-restricted cell-mediated lysis of human oligodendrocytes in vitro: relation with CD56 expression. J Immunol 160: 1606–1611
Becher B, D’Souza S, Troutt A.B., Antel J.P. (1998) Fas expression on human fetal astrocytes without susceptibility to Fas-mediated cytotoxicity. Neuroscience 84(2): 627–634
Cheng Y, Deshmukh M, D’Costa A, Demaro J.A., Gidday J.M., Shah A, Sun Y, Jacquin M.F., Johnson E.M., Holtzman D.M. (1998) Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest 101: 1992–1999
D’Souza S, Alinauskas K, McCrea E, Goodyer C, Antel J.P. (1995) Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. J Neurosci 15: 7293–7300
D’Souza S, Bonetti B, Balasingam V, Cashman N.R., Barker P.A., Troutt A.B., Raine C.S., Antel J.P. (1996a) Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 184: 2361–2370
D’Souza S.D., Alinauskas K.A., Antel J.P. (1996b) Ciliary neurotrophic factor selectively protects human oligodendrocytes from tumor necrosis factor-mediated injury. J Neurosci Res 43: 289–298
De Stefano N, Matthews P.M., Fu L, Narayanan S, Stanley J, Francis G.S., Antel J.P., Arnold D.L. (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121: 1469–1477
Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 184:1513–1518
Jurewicz A, Biddison W.E., Antel J.P. (1998) MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J Immunol 160: 3056–3059
Ladiwala U, Lachance C, Simoneau S.J.J., Barker P.A., Antel J.P. (1997) Adult human oligodendrocytes expressing p75 neurotrophin receptor do not undergo apoptosis in response to NGF. J Neurosci 18: 1297–1300
Ladiwala U, Li H, Antel J.P., Nalbantoglu J (1999) p53 induction by tumor necrosis factor-alpha and involvement of p53 in cen death of human oligodendrocytes. J Neurochem 73: 605–611
Lafortune L, Nalbantoglu J, Antel J.P. (1996) Expression of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6) mRNA in adult human astrocytes: comparison with adult microglia and fetal astrocytes. J Neuropathol Exp Neurol 55: 515–521
Lassmann H, Raine C.S., Antel J, Prineas J.W. (1998) Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 86: 213–217
Lucchinetti C.F., Brück W (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 6: 259–274
Miller S.D., Vanderlugt C.L., Begolka W.S., Pao W, Yauch R.L., Neville KL, Katz-Levy Y, Carrizosa A, Kim B.S. (1997) Persistent infection with Theiler’s virus leads to CNS autoimmunity via epitope spreading. Nat Med 3: 1133–1136
Noble P.G., Antel J.P., Yong V.W. (1994) Astrocytes and catalase prevent the toxicity of catecholamines to oligodendrocytes. Brain Res 633: 83–90
Pouly S, Becher B, Blain M, Antel J.P. (2000) Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J Neuropathol Exp Neurol 59: 280–286
Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L, Kollias G (1997) TNF-alpha transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol 72: 137–141
Raine C.S. (1997) The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol 77: 135–152
Taupin V, Renno T, Bourbonniere L, Peterson A.C., Rodriguez M, Owens T (1997) Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur J Immunol 27: 905–913
Thornberry N.A., Lazebnik Y (1998) Caspases: enemies within. Science 281: 1312–1316
Tran E.H., Hardin-Pouzet H, Verge G, Owens T (1997) Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis. J Neuroimmunol 74: 121–129
Trapp B.D., Peterson J, Ransohoff R.M., Rudick R, Mork S, Bo L (1998) Axonal transecti on in the lesions of multiple sclerosis. N Engl J Med 338: 278–285
Vergelli M, Le H, van Noort J.M., Dhib-Jalbut S, McFarland H, Martin R (1996) A novel population of CD4+CD56+ myelin-reactive T cens lyses target cens expressing CD56/neural cen adhesion molecule. J Immunol 157: 679–688
Yong V.W., Antel J.P. (1997) Culture of glial cens from human brain biopsies. In: Fedoroff S, Richardson A (eds) Protocols for neural cen culture. Humana Press, Totowa NJ, pp 157–173
Zeine R, Pon R, Ladiwala U, Antel J.P., Filion L.G., Freedman M.S. (1998) Mechanism of gammadelta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis. J Neuroimmunol 87: 49–61
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Wien
About this paper
Cite this paper
Pouly, S., Antel, J.P., Ladiwala, U., Nalbantoglu, J., Becher, B. (2000). Mechanisms of tissue injury in multiple sclerosis: opportunities for neuroprotective therapy. In: Mizuno, Y., Calne, D.B., Horowski, R., Poewe, W., Riederer, P., Youdim, M.B.H. (eds) Advances in Research on Neurodegeneration. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6284-2_16
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6284-2_16
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7246-9
Online ISBN: 978-3-7091-6284-2
eBook Packages: Springer Book Archive